hVIVO plc (FRA:CRO)

Market Cap	61.41M -48.1%
Revenue (ttm)	56.93M -25.0%
Net Income	-6.87M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	0.00 (3.06%)
Ex-Dividend Date	May 15, 2025

Volume	n/a
Average Volume	2,002
Open	0.0775
Previous Close	0.0950
Day's Range	0.0775 - 0.0775
52-Week Range	0.0440 - 0.2080
Beta	n/a
RSI	46.85
Earnings Date	Apr 15, 2026

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C...

• Industry: Commercial Physical and Biological Research
• CEO: Yamin Khan
• Employees: 376
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CRO

Financial Performance

Financial numbers in GBP